Navigation Links
Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
Date:5/29/2008

SAN MARINO, Calif., May 29 /PRNewswire/ -- Epeius Biotechnologies (http://www.epeiusbiotech.com) announced today the results of an on-going Phase I/II study of Rexin-G for metastatic bone and soft tissue sarcoma (J Clin Oncol 26: 14509, 2008). Rexin-G is the first and so far only targeted gene therapy vector that has been tested in the clinic (Nature Reviews/Genetics 2007). In this open label study, cohorts of 6 to 7 patients with all types of sarcoma, including osteosarcoma, Ewing's sarcoma, leiomyosarcoma, malignant fibrous histiocytoma, chondrosarcoma, fibrosarcoma, liposarcoma, angiosarcoma, spindle cell sarcoma, and malignant mixed Mullerian tumor of ovary, were treated with 1 x 10e11 cfu Rexin-G, administered i.v. over 5 minutes, 2 times a week for 4 weeks (Cumulative Dose = 8 x 10e11 cfu) followed by a 2-week rest period. Patients with Grade 1 or less toxicity were given progressive intra-patient dose-escalations consisting of additional treatment cycles of 1 to 2 x 10e11 cfu three times a week for 4 weeks (Cumulative Dose per cycle: 1.2-2.4 x 10e12 cfu).

These higher dosing regimens were associated with prolonged disease stabilization and a median overall survival of greater than 6 months, which was three times longer than that observed in the low-dose group. Further, histologic examination of resected tumors showed 50-90% necrosis. No dose-limiting toxicity was observed, even at the higher doses of Rexin-G, thus confirming that repeated infusions of Rexin-G are safe and well-tolerated. Taken together with previous clinical studies conducted in the Philippines and Japan, these studies confirm the exemplary safety and dose-dependent efficacy of Rexin-G in a broad spectrum of chemotherapy-resistant cancers.

For more information about Rexin-G, on-going clinical trials in the USA and abroad, and/or Epeius pathotropic (disease-seeking) gene delivery systems, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.

*(LOGO 72dpi: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Epeius Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
2. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
3. Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders
4. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
5. Genmab Announces Updates on Phase III Cancer Studies
6. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
7. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
8. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
9. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
10. First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer
11. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... July 28, 2017 EnvoyHealth, a Diplomat company, has ... program for CleverCap LITE, a technology designed to improve ... deliver innovative health technology solutions and services that help ... CleverCap LITE offers medication monitoring and ... cover: Records date ...
(Date:7/26/2017)... 2017 E.I. Medical Imaging (EIMI) has partnered ... custom design the worlds first ultrasound system to be used ... native habitat. In preparation for a piece produced by ... Week, Dr. Guttridge approached EIMI with the idea of an ... hammerhead sharks underwater. ...
(Date:7/26/2017)... YORK , July 26, 2017 The ... Annual Prix Galien USA Award Nominees. ... the Prix Galien Award recognizes outstanding biomedical and technology product ... To qualify, each candidate must be U.S. ... last five years and demonstrate tremendous potential to impact human ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... ... past six years, Lightning Labels has sent out a call for users of its custom ... creativity of their designs. Submissions this year were open from May 18 to July 1 ... winners of the sixth annual Photo Contest, along with the prizes they've received:, ...
(Date:8/22/2017)... ... , ... Five Star Glass is new to the Texas market, but is proudly managed by ... most makes and models, in Grand Prairie, TX, located in the center of the DFW ... family owned business for the past 40 years with 32 convenient locations in Texas, Nevada ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Without ... abuse and neglect, and the struggles faced while hoping for a better life. ... published author, Judy Von Bernewitz, who spent 13 years working with deprived/neglected adolescents ...
(Date:8/22/2017)... ... August 22, 2017 , ... John Stewart joins ... Managing Member for t4 Leadership Development & Consulting. He has spent his career ... “success”: physician leadership development, servant leadership, data driven process improvement, and supportive technology. ...
(Date:8/22/2017)... ... 22, 2017 , ... Although Labor Day is not as popular for fireworks ... weekend displays, and numerous households celebrate the unofficial end of summer with backyard fireworks ... pets. , Kris Zambo, owner of Dynamite Fireworks in Hammond, Indiana, ...
Breaking Medicine News(10 mins):